We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Market watch.
- Abstract
The article provides an overview of the market stock performance of biotechnology industries in the U.S. as of July to August 2007. The Nasdaq Biotechnology Index shows the unprogressive biotechnology stocks performance for July to August. The issued ruling for the reduction of erythropoietin utilization by the U.S. reimbursement authorities on July 30 has created a great impact to the product sales growth of Californian-based Amgen Inc. Vertex Inc. of Cambridge, Massachusetts announced good results from its clinical trials of hepatitis C drug, teleprevir, for its second quarter results.
- Subjects
UNITED States; STOCKS (Finance); BIOTECHNOLOGY; NASDAQ Stock Market; BIOTECHNOLOGY industries; ERYTHROPOIETIN; HEALTH insurance reimbursement; AMGEN Inc.; VERTEX Inc.; MARKETING
- Publication
Nature, 2007, Vol 449, Issue 7158, p15
- ISSN
0028-0836
- Publication type
Article
- DOI
10.1038/449015b